Advanced search×

Going off antidepressants. If not handled carefully, coming off your medication can cause disturbing symptoms and set you up for a relapse of depression.

Author(s) unavailable

Harv Womens Health Watch 18(3):1-3 (2010) PMID 21140551

Version: za2963e q8za6 q8zbe q8zc7 q8zd8 q8ze0 q8zff q8zg9

Similar articles you may find interesting…

  1. The age structure of stellar populations in the solar vicinity. Clues of a two-phase formation history of the Milky Way disk
    M Haywood, P Di Matteo, and A Gomez

    arXiv:1305.4663 [astro-ph.GA] 20 May 2013

    We analyze high quality abundances data of solar neighborhood stars and show That there are two distinct regimes of [alpha/Fe] versus age which we identify As the epochs of the thick and thin disk formation. A tight correlation between Metallicity and [alpha/Fe] versus age is clearly identifiable on...
    View PDF
  2. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarab...
    Marino Clavio, Fabio Cruciani, and Marco Gobbi

    Ann Hematol (2013) PMID 23686116

    We report the final results of a prospective trial testing the combination of fludarabine, Ara-C and idarubicin (FLAI) followed by low-dose gemtuzumab ozogamicin (FLAI-GO) in 85 patients aged 60 years or more with CD33+ acute myeloid leukaemia (AML). Median age was 68 years (60-82); karyotype was un...
  3. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarab...
    Marino Clavio, Fabio Cruciani, and Marco Gobbi

    Ann Hematol (2013) PMID 23686116

    We report the final results of a prospective trial testing the combination of fludarabine, Ara-C and idarubicin (FLAI) followed by low-dose gemtuzumab ozogamicin (FLAI-GO) in 85 patients aged 60 years or more with CD33+ acute myeloid leukaemia (AML). Median age was 68 years (60-82); karyotype was un...